Drug Trial Radar · NCT02321267
Cohort Study of the Clinical Course of Macular Diseases in Kagawa
Last checked: Nov 20, 2026Latest source record: Mar 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Dec 2014
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Kagawa UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS). Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Conditions
- Macular Disease
Interventions
ranibizumab, aflibercept, pegaptanib, verteporphinDrug
ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of best-collected visual acuity from baseline at 5 yearsTime frame: Five years after the registration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kagawa University Faculty of Medicine
Hiragi, Kagawa-ken, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.